Hironori Haga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hironori Haga has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Itsuko Koyanagi
2 shared publicationsMasakazu Fujimoto
2 shared publicationsSachiko Minamiguchi
Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Japan
2 shared publications- Tsutomu Chiba
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
2 shared publications Yoichiro Kobashi
Department of Pathology, Tenri Hospital, Nara, Japan
2 shared publicationsYoshiaki Yuba
Department of Pathology
2 shared publications
Latest Publications
- 1 January 2015
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 54 (12) , 1505-1508
Slow Progression of Poorly Differentiated Gastric Carcinoma Associated with Epstein-Barr Virus Infection: 12-year Follow-up
Epstein-Barr virus (EBV)-associated gastric carcinoma accounts for nearly 10% of all gastric carcinomas and has distinct demographic, clinical and pathological features compared with EBV-negative gastric carcinoma. We herein report the case of a patient with EBV-associated gastric carcinoma followed up for 12 years during the natural course of the disease. The appearance of the tumor on gastroscopy and computed tomography gradually changed, and the size of the lesion increased very slowly during the 12 years, without metastasis. The present case indicates that some EBV-associated gastric carcinomas progress very slowly.
- 1 January 2015
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 54 (12) , 1505-1508
Slow Progression of Poorly Differentiated Gastric Carcinoma Associated with Epstein-Barr Virus Infection: 12-year Follow-up
Epstein-Barr virus (EBV)-associated gastric carcinoma accounts for nearly 10% of all gastric carcinomas and has distinct demographic, clinical and pathological features compared with EBV-negative gastric carcinoma. We herein report the case of a patient with EBV-associated gastric carcinoma followed up for 12 years during the natural course of the disease. The appearance of the tumor on gastroscopy and computed tomography gradually changed, and the size of the lesion increased very slowly during the 12 years, without metastasis. The present case indicates that some EBV-associated gastric carcinomas progress very slowly.
- 1 January 2013
- Published by The Japanese Society of Clinical Cytology in The Journal of the Japanese Society of Clinical Cytology
- Vol. 52 (5) , 411-414
Usefulness of PreservCyt^|^reg; Solution as a cytological sample preservation fluid for EGFR gene mutation analysis
目的 : 上皮成長因子受容体 (EGFR) の遺伝子変異を伴う非小細胞肺癌に EGFR-TKI による分子標的治療が有効であり, 治療方針決定には EGFR 遺伝子変異検査が不可欠である. 組織採取が困難な場合, 細胞診検体を用いて確定診断とともに EGFR 遺伝子変異検査を行うが, 細胞診検体の保存方法に関する報告はない. 本研究では EGFR 遺伝子変異解析に供する細胞診検体の保存方法を比較検討した. 方法 : 京都大学医学部附属病院で非小細胞肺癌と診断された症例 24 例 (気管支洗浄液 20 例, 胸水 4 例) を対象とした. 採取した検体はそれぞれ細胞診断用, PreservCyt® Solution (以下 PC 液) による室温保存用, 凍結保存用 (−80°C) の 3 検体に等分した. 遺伝子解析は三菱化学メディエンス社にて PNA-LNA PCR CLAMP 法により行った. 成績 : 凍結保存法と PC 液保存法の EGFR 遺伝子変異陽性率はそれぞれ 50% (12/24), 54% (13/24) で, 1 例のみ 2 つの方法間で乖離を認め, 一致率は 96%と良好だった. 結論 : PC 液を用いた LBC 実施後の残検体は, そのまま EGFR 遺伝子変異検査に使えるため, 円滑な治療方針決定に有用である.
- 1 January 2013
- Published by The Japanese Society of Clinical Cytology in The Journal of the Japanese Society of Clinical Cytology
- Vol. 52 (5) , 411-414
Usefulness of PreservCyt^|^reg; Solution as a cytological sample preservation fluid for EGFR gene mutation analysis
目的 : 上皮成長因子受容体 (EGFR) の遺伝子変異を伴う非小細胞肺癌に EGFR-TKI による分子標的治療が有効であり, 治療方針決定には EGFR 遺伝子変異検査が不可欠である. 組織採取が困難な場合, 細胞診検体を用いて確定診断とともに EGFR 遺伝子変異検査を行うが, 細胞診検体の保存方法に関する報告はない. 本研究では EGFR 遺伝子変異解析に供する細胞診検体の保存方法を比較検討した. 方法 : 京都大学医学部附属病院で非小細胞肺癌と診断された症例 24 例 (気管支洗浄液 20 例, 胸水 4 例) を対象とした. 採取した検体はそれぞれ細胞診断用, PreservCyt® Solution (以下 PC 液) による室温保存用, 凍結保存用 (−80°C) の 3 検体に等分した. 遺伝子解析は三菱化学メディエンス社にて PNA-LNA PCR CLAMP 法により行った. 成績 : 凍結保存法と PC 液保存法の EGFR 遺伝子変異陽性率はそれぞれ 50% (12/24), 54% (13/24) で, 1 例のみ 2 つの方法間で乖離を認め, 一致率は 96%と良好だった. 結論 : PC 液を用いた LBC 実施後の残検体は, そのまま EGFR 遺伝子変異検査に使えるため, 円滑な治療方針決定に有用である.
- Open Access
- 1 January 2013
- Published by Japanese Society of Allergology in Allergology International
- Vol. 62 (1) , 99-104
PD-1 Regulates the Growth of Human Mastocytosis Cells
BackgroundProgrammed death-1 (PD-1) is a marker for human neoplastic T cells. Here, we evaluated whether or not PD-1 was also a marker for human mastocytosis, and explored the role of PD-1 in human mastocytosis cells.MethodsImmunohistochemical analysis was used to evaluate the expression of PD-1 in clinical samples of human cutaneous mastocytosis. The expression of PD-1 in human mastocytosis cell lines was checked by RT- PCR, western blotting and flow cytometry. We stimulated human mastocytosis cell lines (LAD2 and HMC1.2) with recombinant ligand for PD-1, PD-L1 (rPD-L1), and tested the proliferative activity and the status of signal molecules by Cell Counting Kit-8 and ELISA, respectively.ResultsTen of 30 human cutaneous mastocytosis cases (33.3%) expressed PD-1 protein. We also found that a human mastocytosis line LAD2 cells expressed PD-1 protein on their surfaces. The administration with rPD-L1 suppressed the stem cell factor-dependent growth of the LAD2 cells. And, rPD-L1 activated SHP-1 and SHP-2 simultaneously, and decreased the phosphorylation of AKT, in LAD2 cells. In contrast, we could not detect the expression of PD-1, and the significant effect of rPD-L1 on the mutated KIT-driven growth of HMC1.2 cells.ConclusionsPD-1 could be a marker for human cutaneous mastocytosis and regulate the growth of human PD-1-positive mastocytosis cells
- 1 January 2013
- Published by Japanese Society of Allergology in Allergology International
- Vol. 62 (1) , 99-104
Open AccessPD-1 Regulates the Growth of Human Mastocytosis Cells
BackgroundProgrammed death-1 (PD-1) is a marker for human neoplastic T cells. Here, we evaluated whether or not PD-1 was also a marker for human mastocytosis, and explored the role of PD-1 in human mastocytosis cells.MethodsImmunohistochemical analysis was used to evaluate the expression of PD-1 in clinical samples of human cutaneous mastocytosis. The expression of PD-1 in human mastocytosis cell lines was checked by RT- PCR, western blotting and flow cytometry. We stimulated human mastocytosis cell lines (LAD2 and HMC1.2) with recombinant ligand for PD-1, PD-L1 (rPD-L1), and tested the proliferative activity and the status of signal molecules by Cell Counting Kit-8 and ELISA, respectively.ResultsTen of 30 human cutaneous mastocytosis cases (33.3%) expressed PD-1 protein. We also found that a human mastocytosis line LAD2 cells expressed PD-1 protein on their surfaces. The administration with rPD-L1 suppressed the stem cell factor-dependent growth of the LAD2 cells. And, rPD-L1 activated SHP-1 and SHP-2 simultaneously, and decreased the phosphorylation of AKT, in LAD2 cells. In contrast, we could not detect the expression of PD-1, and the significant effect of rPD-L1 on the mutated KIT-driven growth of HMC1.2 cells.ConclusionsPD-1 could be a marker for human cutaneous mastocytosis and regulate the growth of human PD-1-positive mastocytosis cells
- 7 September 2012
- Published by Wiley in Histopathology
- Vol. 61 (6) , 1230-1232
Coexistence of Epstein-Barr virus-associated lymphoproliferative disorder and marginal zone B-cell lymphoma of the thymus in a patient with rheumatoid arthritis treated with methotrexate
- 7 September 2012
- Published by Wiley in Histopathology
- Vol. 61 (6) , 1230-1232
Coexistence of Epstein-Barr virus-associated lymphoproliferative disorder and marginal zone B-cell lymphoma of the thymus in a patient with rheumatoid arthritis treated with methotrexate
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-762-762
355 Limited Benefit of Biochemical Response to Combination Therapy with Interferon and Ribavirin for Patients with Recurrent Hepatitis C After Living-Donor Liver Transplantation
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4) , A-762-762
355 Limited Benefit of Biochemical Response to Combination Therapy with Interferon and Ribavirin for Patients with Recurrent Hepatitis C After Living-Donor Liver Transplantation
- 1 April 2008
- Vol. 49 (4) , 263-9
[Epstein-Barr virus-associated B cell lymphoproliferative disorder complicated in adult T-cell leukemia].
Adult T-cell leukemia (ATL) is accompanied by remarkably impaired cellular immune responses. Reports on the simultaneous development of ATL and Epstein-Barr virus-associated lymphoproliferative disorders (EBV-LPD) are, however, quite rare. A 53-years-old man was admitted to our hospital because of multiple bilateral pulmonary nodules, skin rash, lymphadenopathy, and hypercalcemia. The smear preparation of peripheral blood demonstrated pathological lymphocytes with lobulated nuclei. They expressed CD2, CD3, and CD25, but did not express either CD4 or CD8. In addition, he was positive for Human T-cell leukemic virus type-I (HTLV-I), and monoclonal integration of HTLV-I provirus was detected in peripheral blood. Unexpectedly, inguinal lymph node biopsy showed polyclonal proliferation of EBV-positive large and bizarre-shaped B cells, and monoclonal growth of large abnormal T cells. He was diagnosed as having acute type ATL complicated by EBV-LPD. Chemotherapy for ATL effectively decreased the tumor burden of ATL, but persistent high fever developed suddenly on the 68th day after admission, and he died of multi-organ failure with severe metabolic acidosis. At the time of multi-organ failure, viral load had increased strikingly, suggesting that the progression of EBV-LPD might have been responsible for multi-organ failure in this case.
- 1 April 2008
- Vol. 49 (4) , 263-9
[Epstein-Barr virus-associated B cell lymphoproliferative disorder complicated in adult T-cell leukemia].
Adult T-cell leukemia (ATL) is accompanied by remarkably impaired cellular immune responses. Reports on the simultaneous development of ATL and Epstein-Barr virus-associated lymphoproliferative disorders (EBV-LPD) are, however, quite rare. A 53-years-old man was admitted to our hospital because of multiple bilateral pulmonary nodules, skin rash, lymphadenopathy, and hypercalcemia. The smear preparation of peripheral blood demonstrated pathological lymphocytes with lobulated nuclei. They expressed CD2, CD3, and CD25, but did not express either CD4 or CD8. In addition, he was positive for Human T-cell leukemic virus type-I (HTLV-I), and monoclonal integration of HTLV-I provirus was detected in peripheral blood. Unexpectedly, inguinal lymph node biopsy showed polyclonal proliferation of EBV-positive large and bizarre-shaped B cells, and monoclonal growth of large abnormal T cells. He was diagnosed as having acute type ATL complicated by EBV-LPD. Chemotherapy for ATL effectively decreased the tumor burden of ATL, but persistent high fever developed suddenly on the 68th day after admission, and he died of multi-organ failure with severe metabolic acidosis. At the time of multi-organ failure, viral load had increased strikingly, suggesting that the progression of EBV-LPD might have been responsible for multi-organ failure in this case.
- Open Access
- 1 January 1996
- Published by Japanese Society for Lymphoreticular Tissue Research in Journal of the Japan Society of the Reticuloendothelial System
- Vol. 36 (5) , 363-368
A case of mantle cell lymphoma of the stomach
- 1 January 1996
- Published by Japanese Society for Lymphoreticular Tissue Research in Journal of the Japan Society of the Reticuloendothelial System
- Vol. 36 (5) , 363-368
Open AccessA case of mantle cell lymphoma of the stomach